ArticleJournal of medical case reports2025
Fatal outcome of severe serotonin syndrome and acute respiratory distress syndrome after self-poisoning with paroxetine: a case report.
Article in Journal of medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-marketing safety evaluation of paroxetine: a real-world pharmacovigilance analysis based on the FDA adverse event reporting system.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParoxetine overdose can cause serotonin syndrome, presenting with a constellation of manifestations that range from mild symptoms to life-threatening complications. Current evidence regarding the management of paroxetine-induced serotonin syndrome is limited to case reports and small case series, with no definitive recommendations established from controlled clinical trials in humans. CASE PRESENTATION: In this case report, we describe an exceptional and severe clinical course of a 26-year-old Caucasian female who ingested multiple drugs with suicidal intention-including 4000 mg paroxetine. The patient developed severe serotonin syndrome complicated by acute respiratory distress syndrome, necessitating invasive mechanical ventilation and veno-venous extracorporeal membrane oxygenation. Serotonin syndrome prevailed unusually long, with serum paroxetine levels remaining within the lethal dose range for 20 days postingestion. Despite intensive therapeutic interventions-including CytoSorb™ hemoadsorption, adjunctive corticosteroids, olanzapine (10 mg/day), and maximal intensive care treatment-the patient died on day 20 postingestion.
conclusionOur case illustrates the importance of early and aggressive intervention, while highlighting the limited efficacy of currently available extracorporeal elimination techniques in severe paroxetine overdose. Given the protracted and progressive symptoms observed in this case report and others, clinicians should remain vigilant for pharmacokinetic complications such as pharmacobezoars or poor CYP2D6 metabolism in massive selective serotonin reuptake inhibitor overdose, leading to an early and aggressive treatment in similar cases with serotonin syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.